For the year ending 2025-12-31, LPCN had -$1,000,084 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -9,627,505 |
| Depreciation expense | 60,782 |
| Stock-based compensation expense | 242,497 |
| Amortization of discounts on marketable investment securities | 192,938 |
| Accrued interest income | -106,258 |
| License and royalties receivable | 1,053,985 |
| Prepaid and other current assets | 311,090 |
| Accounts payable | 700,126 |
| Accrued expenses | 315,134 |
| Cash used in operating activities | -9,760,721 |
| Purchases of marketable investment securities | 14,708,915 |
| Maturities of marketable investment securities | 20,600,000 |
| Cash provided by investing activities | 5,891,085 |
| Net proceeds from sale of common stock through atm | 2,869,552 |
| Cash provided by financing activities | 2,869,552 |
| Net increase (decrease) in cash and cash equivalents | -1,000,084 |
| Cash and cash equivalents at beginning of period | 6,205,926 |
| Cash and cash equivalents at end of period | 5,205,842 |
Lipocine Inc. (LPCN)
Lipocine Inc. (LPCN)